The study authors note that the absolute difference between 5 years of aromatase inhibitors and 2 years of tamoxifen then aromatase inhibitors for 3 years is small in terms of clinical relevance, and that efficacy does not differ between the three aromatase inhibitors. Therefore, they add that patient preference, tolerability, and cost should be considered when choosing which schedule and which aromatase inhibitor to include in the therapeutic plan for adjuvant hormonal treatment of postmenopausal patients with early breast cancer.